BIOVIE INC. - COMMON STOCK

BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

26 Sep 2023 08:00:01 By Nasdaq GlobeNewswire

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

19 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

11 Sep 2023 08:00:01 By Nasdaq GlobeNewswire

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023

07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

31 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders

28 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie Issues Letter to Shareholders

18 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

17 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

10 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease

26 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie Set to Join the Russell 2000® and Russell 3000® Indexes

23 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association

21 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress

16 May 2023 16:05:00 By Nasdaq GlobeNewswire

BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting

20 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

17 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023

21 Mar 2023 08:01:00 By Nasdaq GlobeNewswire

BioVie Announces Registration Details for "BioVie Day" Webinar

14 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

13 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference

09 Mar 2023 08:00:01 By Nasdaq GlobeNewswire